37,226 Shares in Pfizer Inc. (NYSE:PFE) Acquired by Wakefield Asset Management LLLP

Wakefield Asset Management LLLP purchased a new position in shares of Pfizer Inc. (NYSE:PFE) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 37,226 shares of the biopharmaceutical company’s stock, valued at approximately $1,458,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of PFE. OLD Mission Capital LLC acquired a new stake in Pfizer in the third quarter valued at approximately $291,000. Lehman & Derafelo Financial Resources LLC lifted its stake in Pfizer by 3.6% in the first quarter. Lehman & Derafelo Financial Resources LLC now owns 212,511 shares of the biopharmaceutical company’s stock valued at $7,699,000 after acquiring an additional 7,354 shares during the last quarter. Ironwood Wealth Management LLC. lifted its stake in Pfizer by 1.6% in the first quarter. Ironwood Wealth Management LLC. now owns 35,385 shares of the biopharmaceutical company’s stock valued at $1,282,000 after acquiring an additional 550 shares during the last quarter. Petix & Botte Co bought a new position in shares of Pfizer in the first quarter valued at approximately $187,000. Finally, Los Angeles Capital Management LLC raised its position in shares of Pfizer by 14.0% in the first quarter. Los Angeles Capital Management LLC now owns 719,120 shares of the biopharmaceutical company’s stock valued at $26,054,000 after purchasing an additional 88,403 shares during the period. Hedge funds and other institutional investors own 64.93% of the company’s stock.

Shares of NYSE:PFE traded up $0.26 on Wednesday, hitting $44.97. The stock had a trading volume of 246,624 shares, compared to its average volume of 30,836,189. Pfizer Inc. has a twelve month low of $33.36 and a twelve month high of $51.86. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.12 and a current ratio of 1.37. The firm’s 50 day moving average price is $44.74 and its 200-day moving average price is $40.35. The company has a market capitalization of $252.13 billion, a price-to-earnings ratio of 19.18, a price-to-earnings-growth ratio of 1.58 and a beta of 0.74.

Pfizer (NYSE:PFE) last issued its earnings results on Wednesday, July 28th. The biopharmaceutical company reported $1.07 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.97 by $0.10. The company had revenue of $18.98 billion for the quarter, compared to the consensus estimate of $17.54 billion. Pfizer had a net margin of 23.06% and a return on equity of 26.49%. During the same quarter in the previous year, the company earned $0.78 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 4.12 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 7th. Investors of record on Friday, July 30th were given a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, July 29th. This represents a $1.56 annualized dividend and a yield of 3.47%. Pfizer’s dividend payout ratio (DPR) is 70.27%.

A number of research firms have recently commented on PFE. JPMorgan Chase & Co. lifted their price target on shares of Pfizer from $40.00 to $42.00 and gave the company a “neutral” rating in a research report on Monday. Morgan Stanley lifted their price target on shares of Pfizer from $42.00 to $45.00 and gave the company an “equal weight” rating in a research report on Thursday, July 29th. Mizuho lifted their price target on shares of Pfizer from $42.00 to $43.00 and gave the company a “neutral” rating in a research report on Friday, July 30th. Royal Bank of Canada set a $44.00 target price on shares of Pfizer in a research report on Thursday, July 29th. Finally, Berenberg Bank reaffirmed a “neutral” rating and set a $43.00 target price on shares of Pfizer in a research report on Tuesday, June 15th. Eleven research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Pfizer has a consensus rating of “Hold” and an average target price of $42.77.

In other Pfizer news, SVP Jennifer B. Damico sold 2,500 shares of the company’s stock in a transaction dated Friday, July 30th. The shares were sold at an average price of $42.86, for a total transaction of $107,150.00. Following the transaction, the senior vice president now directly owns 11,430 shares in the company, valued at approximately $489,889.80. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Jennifer B. Damico sold 1,661 shares of the company’s stock in a transaction dated Friday, August 13th. The shares were sold at an average price of $48.30, for a total transaction of $80,226.30. The disclosure for this sale can be found here. 0.05% of the stock is owned by corporate insiders.

About Pfizer

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Featured Article: What is the CBOE Russell 2000® Volatility Index?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.